Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (October 2013)
22 slides from Patrys's shareholder meeting presentation, Oct 23, 2013
Slide 1: Annual General Meeting
For personal use only Annual General Meeting Dr. Marie Roskrow, CEO & Managing Director 23 October 2013 ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Patrys Limited to be materially different
Slide 3: Patrys in 2013
Patrys in 2013 For personal use only o Oncology-focussed clinical-stage Company o Deep pipeline of novel cancer-specific IgM monoclonal antibodies o Treasure-trove of novel cancer targets o Significant intellectual property portfolio o Network of Internationally-renowned collaborators o Experienced
Slide 4: Experienced & Capable Team
Experienced & Capable Team For personal use only Marie Roskrow CEO & MD Frank Hensel VP Research & Development Deanne Greenwood Senior Director Business Development Valentina Dubljevic Senior Director Operations Stephanie Brändlein Research Group Leader Immunology Roger McPherson CFO & Company Secre
Slide 5: Pipeline
Pipeline For personal use only Product Discovery Preclinical Phase I Phase 2a (Target) Phase I PAT-SM6 Melanoma Completed (GRP78) Phase I/IIa PAT-SM6 Multiple Myeloma Commenced (GRP78) 4Q2012 PAT-LM1 Solid Tumours (NONO) Phase I/IIa Completed PAT-SC1 Gastric Cancer Out- Licensing (CD55) Candidate PA
Slide 6: FY13 Programme Highlights – I
FY13 Programme Highlights – I For personal use only PAT-SM6: Phase I/IIa multi-dose multiple myeloma trial: o Conducted at University Hospital, Würzburg, Germany o Commenced Nov. 2012, estimated 1yr complete enrolment o Currently in 4th (final) dosing cohort o Full data to be released 1Q 2014 o Ongo
Slide 7: FY13 Programme Highlights – II
FY13 Programme Highlights – II For personal use only PAT-LM1: o Key patent granted around use of PAT-LM1 for treatment / prevention of metastatic cancer o Moved recombinant cell line through development / early scale-up o Promising preclinical data in leukemia (ongoing) o External collaboration with
Slide 8: PAT-SM6
For personal use only PAT-SM6
Slide 9: Patrys' Lead Antibody: PAT-SM6
Patrys’ Lead Antibody: PAT-SM6 For personal use only PAT-SM6: o IgM isotype, λ-light chain o Isolated from stomach cancer patient o Targets tumour specific epitope on GRP78 o Binds also to oxidised LDL and VLDL Mode of Action: o Internalisation upon binding of oxidised LDL & GRP78PAT-SM6 o Internali
Slide 10: Multiple Myeloma - Opportunity
Multiple MultipleMyeloma Myeloma- Opportunity – Opportunity For personal use only o Cancer of the plasma cells in bone marrow. Cells grow out of control and form tumours in solid bone, cause damage to other organs o Estimated to be more than 220,000 cases worldwide and incidence increasing o 5 year
Slide 11: Multiple Myeloma – Pathology
Multiple Myeloma – Pathology For personal use only o Abnormal plasma cells (myeloma o Monoclonal gammopathy detected cells) secrete lots of “useless” by electrophoresis antibodies (M proteins) o Myeloma cells crowd out other blood cells resulting in anaemia, thrombocytopenia (bleeding) and leucopeni
Slide 12: Multiple Myeloma – Presentation
Multiple Myeloma – Presentation For personal use only o Bone disease and hypercalcaemia o Abnormal protein deposits o Bone marrow failure 12 Annual General Meeting October 2013
Slide 13: Therapies for Multiple Myeloma
Therapies for Multiple Myeloma For personal use only Proteosome inhibitors Stem cell transplantation o Bortezomib (Velcade) o Autologous o Carfilzomib (Kyprolis) o Allogeneic Clinical studies IMIDs o Small molecules o Lanalidomide (Revlimid) o Antibodies, peptides o Pomalyst (Pomalidomide) o Immunot
Slide 14: Antibodies in Clinical Trials for MM
Antibodies in Clinical Trials for MM For personal use only MOR 202 PAT-SM6 (MorphoSys/Celgene, Phase I/II) (Patrys Limited, Phase I/IIa) Daratumumab (Genmab/Janssen Biotech, Phase I/II) Elotuzumab (BSM/Abbott, Phase III) GRP78 BHQ880 (Novartis, Phase II) CD138 toxin- conjugated (BT062, Biotest AG, P
Slide 15: Multiple Myeloma Clinical Trial
Multiple Myeloma Clinical Trial For personal use only o Phase I/IIa open-label multi- Clinical Trial Design dose trial in relapsed and Screening Day -14 to -1 multi-resistant patients (N=12 in 4 escalating dosing groups) Treatment Day 1, 3, 8, 10 with PAT-SM6 o 4 cohorts (0.3mg/kg, 1mg/kg, Ambulator
Slide 16: PAT-SM6 Binds to MM Cells in vivo
PAT-SM6 Binds to MM Cells in vivo For personal use only o CD138 positive tumour cells obtained from peripheral blood (Patient 02-002) before and after treatment with PAT-SM6 anti-ID CD138 merge Pre-Treatment Post-Treatment 16 Annual General Meeting October 2013
Slide 17: Initial Clinical Data – I
Initial Clinical Data – I For personal use only o To date: 9 patients treated with 4 doses PAT-SM6 in 3 dose cohorts (0.3mg/kg, 1mg/kg, and 3mg/kg). 4th cohort (6mg/kg/dose) currently underway o PAT-SM6 safe in all patients so far. No dose limiting toxicity (DLT), no related serious adverse events (
Slide 18: Initial Clinical Data – II
Initial Clinical Initial DataData – II Clinical For personal use only Preliminary Efficacy Changes in M-Protein from baseline at D36/EOT 140% 120% 114% 100% 80% Stable Stable disease disease 60% 54% 48% 42% 40% 36.30% 40% 20% 13% 1.40% 0% 01-001 01-002 01-003 02-001 02-002 02-003 03-001 03-002 03-00
Slide 19: Initial Clinical Data – III
Initial Clinical Data – III For personal use only Patient Time to next therapy Salvage regimen Response Novel agents before to salvage PAT-SM6 01-001 28 days VRCD PR Velcade 01-002 9 days Benda, Pred, Thal VGPR Revlimid, Bortezomib 01-003 75 days Treosulfan SD Revlimid 02-001 8 days Benda, Velcade P
Slide 20: Future Options for PAT-SM6
Future Options for PAT-SM6 For personal use only Option 1: Look for a partner now. No further internal clinical development Product Stage of Partners Date Values (Type) Development Kyprolis September Amgen & Onyx o $10.4B cash (Proteasome Marketed US 2013 inhibitor) o Upfront $92 M MOR202 Phase I/II
Slide 21: End 2013 / 2014 Projected Milestones
End 2013 / 2014 Projected Milestones For personal use only Key Milestone Projected Timing (CY) PAT-SM6: o MM, melanoma and GRP78 preclinical data published 1H, 2013 o European orphan drug status obtained 2H, 2013 o Complete Phase I/IIa multiple myeloma (MM) trial enrolment 4Q, 2013 o MM data pre
Slide 22: For Further Information
For personal use only For Further Information Contact Details: Dr. Marie Roskrow, Chief Executive Officer Dr. Deanne Greenwood, Senior Director Business Development Mr. Roger McPherson, Chief Financial Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com